4-Star Stocks Poised to Pop: FMC

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, agricultural company FMC (NYSE: FMC  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at FMC's business and see what CAPS investors are saying about the stock right now.

FMC facts

Headquarters (founded) Philadelphia (1884)
Market Cap $6.7 billion
Industry Diversified chemicals
Trailing-12-Month Revenue $3.5 billion
Management CEO Dr. Pierre Brondeau (since 2010)
CFO William Kim Foster (since 2001)
Return on Equity (average, past 3 years) 25.7%
Cash/Debt $70.8 million / $946.5 million
Dividend Yield 0.7%
Competitors Asahi Glass
Dow Chemical
DuPont

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 418 members who have rated FMC believe the stock will outperform the S&P 500 going forward.  

Just last week, one of those bulls, ice23bear, touched on the growth tailwinds working in FMC's favor: "A strong US company ... good exposure to South America and doing well there even in the current economic conditions. Potential for a good upside if South America as a whole outgrows the US, regardless of which S.A. countries have the best growth in the region."

If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, FMC may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 04, 2012, at 2:04 PM, MrSinnister wrote:

    Why not do an in-depth research report on both why Discovery Labs isn't moving and why now is the perfect time to both invest in Biotechs and DSCO? They have been major M&A targets the past Spring, and I don't see that stopping in the near future.

    Received FDA approval for 1 of its drugs, SURFAXIN, and its nebulizer Affectair on March 5th of this year. PPS Spiked at 5.39 until a week later, a secondary offering of 16 million shares @2.80 was submitted, killing the momentum from the FDA approval and leaving it in the doldrums where it sits today, lagging behind companies with only ONE drug and deeply in the red like Seattle Genetics SGEN, currently trading at over 19. DSCO is slated to have it's distribution pipeline for its infant RDS (Respiratory Distress Syndrome) drug out by the end of the year, with EU approval next year. Trading at currently 2.52, this stock could be the steal of the year, and can actually beat Bank of America (before the crises) as comeback stock or Stock of the Year. The volume is currently dismal as longs have rooted into their positions and currently not selling. Check it out and do your own due diligence.

Add your comment.

DocumentId: 1902238, ~/Articles/ArticleHandler.aspx, 4/23/2014 4:28:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement